INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law Firm
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law Firm
PR Newswire
NEW YORK, Oct. 19, 2026
- Beta Bionics, Inc. (NASDAQ: BBNX) shareholders should email fletcher@fmoorelaw.com
NEW YORK, Oct. 19, 2026 /PRNewswire/ --
What is the Investigation About?
On January 8, 2026, after the market closed, Beta Bionics reported an unexpected shortfall in new patient starts for its iLet Bionic Pancreas insulin pump. This announcement followed a December 2025 report by The Capitol Forum that made public an FDA Form 483 concerning the device.
Following this news, the price of Beta Bionics stock fell $11.85 per share, or approximately 37%, to close at $20.14 per share on January 9, 2026.
On January 30, 2026, Beta Bionics disclosed that the FDA had issued a warning letter related to the earlier inspection observations. The concerns extended beyond complaint handling to its quality management system, medical device reporting, and corrective actions. On February 24, 2026, the FDA publicly released the warning letter, stating that malfunctions potentially causing death or serious injury must be reported, including hypoglycemic episodes requiring medical intervention even when resolved with glucose drinks or candy.
If you own Beta Bionics, Inc. (NASDAQ: BBNX) securities, please contact Fletcher Moore at fletcher@fmoorelaw.com.
You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
MOORE LAW PLLC
30 Wall Street, 8th Floor
New York, NY 10005
fletcher@fmoorelaw.com
www.fmoorelaw.com
SOURCE Moore Law PLLC
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
United States